Sangamo Biosciences (SGMO) has disclosed a new risk, in the Regulation category.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sangamo Biosciences faces a precarious financial future, as its cash reserves are projected to sustain operations only until the third quarter of 2024. Despite active efforts to raise additional capital, the company’s inability to secure further funding has compelled it to consider bankruptcy protection as a possible recourse. Should Sangamo file for bankruptcy, the company’s operational continuity, product development, and overall survival would be fraught with uncertainty, including potential liquidation. This scenario poses a stark risk for common stockholders who may confront total loss of their investment.
The average SGMO stock price target is $2.00, implying 154.74% upside potential.
To learn more about Sangamo Biosciences’ risk factors, click here.
